DC lobby day - April 25, 2018
On February 7, 2014, President Obama signed the Farm Bill of 2013 into law. Section 7606 of the act, Legitimacy of Industrial Hemp Research, defines industrial hemp as distinct from marijuana and authorizes institutions of higher education or state department's of agriculture in states that legalized hemp cultivation to regulate and conduct research and pilot programs.
For more information go to http://www.votehemp.com/2014_farm_bill_section_7606.html
2018 Legislation Update - The senate under the leadership of Mitch McConnell has conditionally approved the Farm Bill with Hemp. Congress has approved much the same with a very narrow vote but without additional hemp language. The Senate & Congress are supporters! There are now 40 states have legalized under research and pilot programs.
Team included: Rusty Hendrickson, Alex Barnett, Michael French, Soheil Samimi, Adam Zuniga, Brian King, Reid Parr & Norm Turnbull
Hemp Pilot Programs Authorized in 2014 Farm Bill
Fifteen states had hemp pilot programs or research in 2016: Colorado, Hawaii, Kentucky, Indiana, Maine, Minnesota, Nebraska, Nevada, New York, North Dakota, Oregon, Tennessee, Vermont, Virginia and West Virginia http://www.votehemp.com/us-state-industrial-hemp-legislation.html
2017 Legislation Update - 38 states and Puerto Rico considered legislation related to industrial hemp in 2017. These bills ranged from clarifying existing laws to establishing new licensing requirements and programs. At least 15 states enacted legislation in 2017 - Arkansas, Colorado, Florida, Hawaii, North Dakota, Nevada, New York, Oregon, South Carolina, Tennessee, Virginia, Washington, West Virginia, Wisconsin and Wyoming. Florida, Wisconsin and Nevada authorized new research or pilot programs. The governors of Arizona and New Mexico vetoed legislation, which would have established new research programs. http://www.ncsl.org/research/agriculture-and-rural-development/state-industrial-hemp-statutes.aspx
AgTech Scientific at the State Capitol
Left to right: Brian King - AgTech Scientific CSO, Tess Simon - KY Cabinet for Economic Development, Gabe Nickell - GOAP/CDBG
Michael French -EPS, Gordon Wilson - Economic Development Bourbon County
- USDA Confirms the Legality of Interstate Sale of Farm Bill Hemp: DEA’s mixed messages about the legality of hemp grown in Farm Bill states prompted the National Hemp Association to facilitate a letter to the Pennsylvania Department of Agriculture from USDA Acting Under Secretary Ann Bartuska, which confirmed the protections of the Farm Bill and Omnibus Law. In pertinent part, USDA stated: “We think it is clear that section 7606 [of the Farm Bill] contemplated the sale and transport of industrial hemp for purposes of the pilot programs authorized by section 7606 under a limited set of circumstances; namely, those involving the study of industrial hemp marketing.”
- International Organizations Reject Restrictions on Cannabidiol (CBD): The hemp-derived CBD industry received an enormous boost in September, when the World Anti-Doping Agency dropped CBD from its list of prohibited substances. An even bigger development occurred in November, when the World Health Organization’s Expert Committee on Drug Dependence issued a reportopining that naturally occurring CBD is safe and well-tolerated in humans (and animals), and is not linked with any negative public health concerns. Furthermore, the Organization concluded that CBD does not induce physical dependence and is not associated with abuse potential: “To date, there is no evidence of recreational use of CBD or any public health related problems with the use of pure CBD.” While these declarations are not binding on U.S. law or public policy, the pronouncements of these respected international agencies could be very influential in the development of stronger U.S. public policies.
- FDA Issues New Warning Letters on CBD, but Limited to Medicinal Claims: While FDA’s 2015 website posting “FDA and Marijuana: Questions & Answers” has caused considerable angst in the industry – in part because FDA tentatively concludes that CBD cannot be sold as a dietary supplement – to date, FDA has only issued Warning Letters to those CBD companies that have made medicinal claims about their products and/or false claims about their CBD content. In November, FDA issued its latest set of Warning Letters, which focused on CBD products being marketed as a treatment for cancer